Study (trial identifier) | Median age (years) | Male | ECOG 0‒1/KPS ≥80 | Prognostic model | Favorable/intermediate/poor risk (%) | Prior nephrectomy | Prior systemic treatments (n) |
Amin et al33 (CheckMate 016) | 57 (38–75) | 26 (79%) | 33 (100%) | MSKCC | 48.5/48.5/3 | 33 (100%) | ≥0 |
Amin et al33 (CheckMate 016) | 56 (40–72) | 18 (90%) | 20 (100%) | MSKCC | 20/70/10 | 20 (100%) | ≥1 |
Atkins et al39 (NCT02133742) | 63 (57–67.5)* | 41 (79%) | 52 (100%) | IMDC | 46/44/6 | 52 (100%) | 0 |
Choueiri et al40 (JAVELIN Renal 101) | 62 (29–83) | 316 (72%) | 442 (100%) | IMDC | 21.3/61.3/16.3 | 352 (80%) | 0 |
Dudek et al34 (BTCRC-GU14-003) | 55 (33–68) | 11 (85%) | 11 (85%) | IMDC | 38.5/23.1/38.5 | 11 (85%) | ≥1 |
Dudek et al34 (BTCRC-GU14-003) | 61 (42–84) | 33 (69%) | 45 (94%) | IMDC | 20.8/64.6/14.6 | 43 (90%) | 0 |
Hammers et al35 (CheckMate 016) | 54 (26–68) | 43 (92%) | 47 (100%) | MSKCC | 44.7/48.9/6.4 | 46 (98%) | ≥0 |
Hammers et al35 2017 (CheckMate 016) | 56 (20–76) | 36 (77%) | 47 (100%) | MSKCC | 44.7/48.9/6.4 | 46 (98%) | ≥0 |
McKay et al41 (OMNIVORE) | – | – | – | IMDC | 33.3/58.3/8.3 | – | 0‒2 |
Motzer et al37 2020 (CheckMate 025) | 62 (23–88) | 315 (77%) | 386 (94%) | MSKCC | 35/49/16 | 364 (89%) | 1‒2 |
Motzer et al42 (CheckMate 214) | 62 (26–85) | 413 (75%) | – | IMDC | 22.7/60.7/16.5 | 453 (82%) | ≥0 |
Naing et al43 (IVY) | 66 (51–69)* | 27 (71%) | 38 (100%) | IMDC | 16/76/8 | – | ≥0 |
Ornstein et al18 (NCT03126331) | 66 (57–72) | 5 (100%) | 5 (100%) | IMDC | 0/100/0 | 5 (100%) | 1‒2 |
Topalian et al38 (CA209-003) | 58 (35–74) | 26 (77%) | 34 (100%) | – | – | 32 (94%) | ≥1 |
Vaishampayan et al36 (JAVELIN Solid Tumor) | 62 (36–85) | 43 (69%) | 62 (100%) | IMDC | 38.7/43.5/17.7 | – | 0 |
Vaishampayan et al36 (JAVELIN Solid Tumor) | 69 (30–80) | 15 (75%) | 20 (100%) | IMDC | 25/65/10 | – | 1 |
Data are presented as median (range) or number of patients (%), unless otherwise stated.
*IQR.
ECOG, Eastern Cooperative Oncology Group; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; KPS, Karnofsky Performance Score; MSKCC, Memorial Sloan Kettering Cancer Center.